October 30, 2023 01:50 PM EDTUpdated 02:05 PM

Senate Democrats urge Biden administration to require insurers to cover OTC birth control

Lia DeGroot

As the legal landscape for reproductive rights in the US remains in flux, Democrats in the Senate are calling on the Biden administration to require …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Senate Democrats urge Biden administration to require insurers to cover OTC birth control

Lia DeGroot

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Biotech industry worries over potential for RFK Jr. ally as FDA pick

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Eisai slashes Leqembi sales forecast by almost $100M

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Sen­ate De­moc­rats urge Biden ad­min­is­tra­tion to re­quire in­sur­ers to cov­er OTC birth con­trol

Lia DeGroot

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Ei­sai slash­es Leqem­bi sales fore­cast by al­most $100M

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Senate Democrats urge Biden administration to require insurers to cover OTC birth control

Biotech industry worries over potential for RFK Jr. ally as FDA pick

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Eisai slashes Leqembi sales forecast by almost $100M

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks